Biotechnology company focused on gastrointestinal diseases and innovative therapies.
Ironwood Pharmaceuticals, Inc. is a dynamic healthcare company specializing in the development and global commercialization of gastrointestinal (GI) products. Among its flagship offerings is linaclotide, marketed under the LINZESS name in the United States and Mexico, and as CONSTELLA in Canada and the European Union. Linaclotide, a guanylate cyclase type-C agonist, is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), representing a significant advancement in GI therapy.
In addition to linaclotide, Ironwood Pharmaceuticals is actively advancing its pipeline with promising candidates such as IW-3300, a GC-C agonist designed to address visceral pain conditions including interstitial cystitis/bladder pain syndrome and endometriosis. Furthermore, the company is developing CNP-104, an immune nanoparticle targeting biliary cholangitis, underscoring its commitment to pioneering therapies for complex GI and related disorders.
Ironwood Pharmaceuticals has established strategic partnerships with industry leaders including AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. These collaborations are pivotal in advancing the development and commercialization of linaclotide globally, while also bolstering the company's capability to innovate and expand its therapeutic portfolio.
Originally incorporated as Microbia, Inc., Ironwood Pharmaceuticals rebranded in April 2008 to reflect its focus on transformative GI treatments. Headquartered in Boston, Massachusetts, since its inception in 1998, Ironwood Pharmaceuticals continues to drive forward with a commitment to addressing unmet medical needs through cutting-edge research, strategic partnerships, and a dedication to improving patient outcomes in gastrointestinal health.